

Company Profiles

Acologix, Inc.	2	Inviragen, Inc.	39
Advinus Therapeutics Pvt. Ltd.	3	Johnson & Johnson	40
Ajinomoto Co., Inc.	4	Jubilant Biosys Pvt. Ltd.	41
Alexandria Real Estate Equities, Inc.	5	Kemwell Pvt. Ltd.	42
Anand And Anand.	6	Livwel Therapeutics, Inc.	43
AstraZeneca, Inc.	7	Lupin Ltd. (Biotech Div.)	44
Atharva Lifesciences Consulting Pvt. Ltd.	8	MakroCare	45
Aurigene Discovery Technologies, Ltd.	9	Medicamentos Especializados S.A.	46
Avogadro.	10	MedTRACK	47
Biocon, Ltd.	11	Merck & Co, Inc.	48
Biomedical Consulting India Pvt. Ltd.	12	Merck Ltd. India.	49
BioXcel Corporation	13	Novartis India Limited	50
Cellworks Research India Pvt. Ltd.	14	Novo Nordisk A/S.	51
Connexios Life Sciences Pvt. Ltd.	15	Orbimed Advisors India Private Limited.	52
Curevac GmbH.	16	Polyclone Bioservices Pvt. Ltd.	53
Cydex Pharmaceuticals, Inc.	17	Quintiles.	54
Dabur Research Foundation	18	Recordati S.p.A.	55
DesignMedix, Inc.	19	Roche	56
Development Centre For Biotechnology	20	RxMD	57
Eli Lilly & Company.	22	Sanofi Pasteur SA.	58
ERA Consulting Group	23	Sathguru Management Consultants Pvt. Ltd.	59
Ernst & Young, LLP	24	SEDICO Pharmaceutical Co.	60
Ethicare Clinical Trial Services.	25	Shire Pharmaceuticals, Inc.	62
Federated Kaufmann Fund.	26	Shook, Hardy & Bacon LLP	63
Fulcrum Pharma plc.	27	Spectrum Pharmaceuticals, Inc.	64
G7 Synergion Pvt. Ltd.	28	State Government of Victoria.	65
Genelogic-Ocimum	29	Strand Life Sciences Pvt. Ltd.	66
Genotypic Technology Pvt. Ltd.	31	Takeda Pharmaceutical Company Limited.	67
GlaxoSmithKline	32	TriStar Technology Group, LLC.	68
Grunenthal GmbH	33	Unique Biotech Limited.	69
GVK Biosciences Private Limited	34	Valletta Health BV	70
Helsinn Healthcare SA	35	Vivo Ventures, LLC	71
Incozen Therapeutics Pvt. Ltd.	36	Vlfe Sciences Tech Pvt. Ltd.	72
Intas Biopharmaceuticals Limited.	37	Zydus Cadila Healthcare Ltd.	73
Intrexon Corporation	38		

Acologix, Inc.

DELEGATE(S) Yoshinari Kumagai

3960 Point Eden Way
Hayward, CA 94545
USA

www.acologix.com

Incorporated:

Employees:

Ownership:

HIGHLIGHTS

Recent

Upcoming

in vitro

MISSION/BACKGROUND

Acologix is a biopharmaceutical company focusing on development of novel therapeutic products in osteo-renal (hard tissue and kidney) area. The company's most advanced compound AC-820 is in Phase 3 stage for treatment of pruritus in kidney dialysis and other conditions. Acologix has completed the SPA process with the FDA on the protocol for its upcoming Phase 3 trial. The compound was launched in Japan in March 2009 and has shown strong sales performance. The first FY annual sales exceeded US \$40 million. The second program at Acologix is a Phase 2 stage hard tissue reparative factor, AC-100. AC-100 has demonstrated selective growth activities of cartilage tissues in the knee cartilage defect models. It promotes differentiation of human chondrocytes.

ALLIANCES

Most of the pipeline compounds at Acologix were either in-licensed from or assigned by the academic institutions through the company's sponsorship on specific therapeutic target identification research programs conducted in those institutions. For instance, AC-200 was in-licensed from the University College London for its worldwide commercial rights.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
			NDA filing
AC-820	Phase II, IIa, IIb	Hepatic pruritus, atopic dermatitis, and other itching conditions	Expand indications to multiple itch conditions
AC-100	Phase I	Cartilage repair for RA, OA, and trauma	Initiate Phase 2
AC-100	Phase II, IIa, IIb	Bone repair	Initiate Phase 2 for closed fracture
AC-100	Phase II, IIa, IIb	Dental care	Initiate Phase 2b/3
AC-200	Preclinical	CKD-MBD, Hyperparathyroidism, Hyperphosphatemia	IND

Advinus Therapeutics Pvt. Ltd.

Rashmi Barbhैया, CEO & MD
Sivaram V, Director, Business Development
Anjal Cheema, Deputy Manager, Business Development

www.advinus.com

Recent

Upcoming

First out licensing of an Advinus discovered molecule in 2010/11.

Two new molecules are expected to be confirmed as clinical candidates in early 2010 for COPD and Diabetes and expected to enter pre-clinical development in 2010.

Expansion of our service offerings to Discovery services.

80,000 sq. ft. and 240,000 sq. ft., respectively.

Advinus Therapeutics is a research based Pharma Company promoted by the TATA group. We offer end-to-end discovery and development services to the global Pharma and Biotech industry while creating long term value through internal and collaborative Drug Discovery.

Of the two core operations of the company, Advinus Drug Discovery, based out of a state-of-the-art facility in Pune, aims to generate its own drug candidates with the objective of out-licensing them at preclinical or clinical stage. The primary focus of the company's discovery efforts are in Metabolic Diseases, Inflammatory Diseases and Neglected Diseases. Towards this end, Advinus has established drug discovery and development collaborations with Merck, Ortho-McNeil-Janssen Pharmaceuticals Inc. and DNDi. Advinus has received the approval for starting the Phase I clinical trials for its internally discovered novel molecule on type II diabetes and FIH trials have been initiated during last week of March 2010.

Advinus' Bangalore facility provides integrated services for preclinical drug development which include - Process Development and Synthesis, Analytical R&D, Drug Metabolism and Pharmacokinetics, Bioanalytical support, Safety Pharmacology, and Toxicology. The center is also one of the most accredited facilities of Asia Pacific with accreditation of its animal facility from AAALAC International and from the German, Dutch and Indian authorities for GLP compliance.

Advinus has completed 14 IND pharm-tox packages in the last 2 years. The data from these studies has been accepted by the USFDA, EMEA, TPP Health Canada, New Zealand and Indian regulatory authorities. In addition Advinus has completed many long term toxicology studies to support NDA filing.

1. Merck Alliance – November 2006

2. DNDi (Swiss non-profit organization) – October 2007

ation for the identification and development of novel therapies for Visceral Leishmaniasis (Kala Azaar) - a fatal disease of the Tropics

3. Novartis - December 2007

4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) – September 2008

Ajinomoto Co., Inc.

1-1 Irifune 2-chome, Chuo-ku
Tokyo 104-0042
Japan
www.ajinomoto.com

metabolism and renal diseases). There is no criterion for developmental stages; however, early stage program is preferable for program in metabolic disease field.

Alexandria Real Estate Equities, Inc.



385 E. Colorado Boulevard
Pasadena, CA 91101
USA

www.labspace.com

New York Stock Exchange: ARE

Alexandria Centre™ for Science and Innovation - India is located in Genome Valley, Shameerpet Cluster, Hyderabad. This is a one of its kind R&D focused centre with unmatched amenities and a world class facility.

Alexandria Real Estate Equities, Inc. (NYSE:ARE), Landlord of Choice to the Life Science Industry®, is the largest owner and preeminent real estate investment trust (“REIT”) focused principally on cluster development through the ownership, operation, management, selective redevelopment, development, and acquisition of properties containing life science laboratory space. Alexandria has a stellar twelve-year operating and financial track record as a NYSE-listed company, ranking fifth out of all publicly traded equity REITs in total return performance, and had an approximate USD \$5.8 billion total market capitalization as of December 31, 2009. Alexandria is the leading provider of high-quality, environmentally sustainable real estate, technical infrastructure, and services to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biotechnology, medical device, product, service, and translational entities, as well as government agencies. Alexandria’s operating platform is based on the principle of “clustering,” with assets and operations located in key life science markets.

As Alexandria continues to expand our dominate position in each of our strategic U.S. cluster markets, we are forging the international extension of our proprietary operating platform by launching what we have mastered domestically into new global markets. Alexandria’s capacity to assemble and fuse the principal elements crucial to developing a successful science and technology driven cluster—location, talent, science/technology, and capital— has positively differentiated our brand and is being actively sought by scientific cluster markets around the world.

Neeti Wilson, PhilD, Esq, MSc,BSc, Managing Associate
Archana Shanker , BSc,LLB, Senior Partner
Pravin Anand , BSc,LLB, Managing Partner

B-41, Nizamuddin East
New Delhi 110013
India

1923
Private

Anand and Anand is a full service Intellectual Property law firm that advises the world's leading companies and institutions. This specialized practice has been servicing a diverse portfolio of clients worldwide since the year 1923; a long tradition of over eight decades.

The firm has an outstanding reputation for innovation and developing creative solutions. The firm works with the endeavor of providing its clients with the best quality of service possible. The central goal underpinning this client care objective is that our lawyers

provide commercial advice to clients which is clear and based on a real understanding of issues in Intellectual Property management in India.

Anand and Anand's fully focused approach has earned it the reputation of being the top Intellectual property law firm in the country. The Firm has been consistently and unanimously rated as India's leading Intellectual property firm in all fields, including, Trademarks and Patents. Anand and Anand is conspicuous as the only Indian firm listed among the World's Best Intellectual Property Practices in Global Counsel 3000 as well as The Asia Pacific Legal 500.

Practice areas broadly include Trademarks, Copyrights, Patent, Design, Litigation, IT, Entertainment, Sports Law and Transactional work.

AstraZeneca, Inc.

Jitendra Patel, PhD
Lena Martensson
Magnus Bjorsne

www.astrazeneca.com/partnering

New York Stock Exchange: AZN

HIGHLIGHTS

AstraZeneca is a major international research based pharmaceutical company engaged in the development, manufacture and marketing of ethical (prescription) pharmaceutical products. Our long heritage of innovation and documented ability to develop new concepts in medicine has made us one of the world's leading pharmaceutical companies. As one of the world's leading pharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that make a real difference in important areas of healthcare.

TECHNOLOGY

ALLIANCES

Atharva Lifesciences Consulting Pvt. Ltd.


11, Nandidurg Road Jayamahala
Extension
Karnataka 560046
India
www.atharvalife.com

t to the extent of 60% in time and expense.

While India continues to be the core focus of Atharva Lifesciences Consulting, the firm has also delivered projects related to other geographies. In Brazil, we mapped out the pharmaceutical and biotech industry – the first ever such exercise in English.

In its team, Atharva Lifesciences has experienced analysts who interact with its numerous consultants, and key opinion leaders in the industry to provide timely and up to date information.

Aurigene Discovery Technologies, Ltd.




Avogadro


Parc de Génibrat
31470 Fontenilles
France

-lab.com

Quality Control, Bioanalysis (LC/MS/MS assays), ADME (including metabolite profiling and identification), Pharmacokinetics (Bioavailability, Bioequivalence), Residues, Target Animal Safety and Environmental Impact Assessment and Biochemistry (lipoprotein profiles, Protein analysis). PHARMACEUTICAL ANALYSIS: Development, validation and transfer of analytical methods; Stability testing of active substances, medicinal products & clinical batches (ICH/VICH). CMC & RA: Constitution of Quality Files and Variation Dossiers; Quality file is built on the basis of data; Technical and regulatory assistance for the development of New Medicinal Products and Generics; Assessment of Existing Dossiers & Drug Master Files (DMF); Update of existing dossiers; Constitution of answers to agencies questions. QUALITY CONTROL: Physico-chemical characterization on various products; Limit tests (residual solvents, heavy metals); Sourcing of active ingredients; Analytical batch release (clinical batches & marketed products). BIOANALYTICAL CHEMISTRY & DRUG METABOLISM: Development & validation of analytical methods; Pharmacokinetic studies, bioavailability, bioequivalence; Early PK studies; Metabolism studies (ADME); Residue depletion studies; Ecotoxicological studies. IN-LIFE PHASE STUDIES: Laboratory species; Food-producing species; Local & general tolerance studies in target species. BIOCHEMISTRY: Lipoprotein profiles; Protein analysis. QUALITY: Full GLP compliance; Full GMP compliance (QC analysis, stability studies); ISO 14001 certification (Environment Management System).

ANALYTICAL TECHNIQUES USING: UPLC system, HPLC system coupled with UV detector, DAD, fluorimeter; LC/MS/MS; GC/FID; GC/MS (EI, CI); GC/HeadSpace; Stability chambers under ICH conditions + photostability; ADME: radiolabeled studies; Equipment for automated solid-phase extraction system; Automated biochemistry analyzer.





BioXcel Corporation



Incorporated:
Employees:
Ownership:

BioXcel Corporation, a premier analytics and knowledge management company with headquarters in Connecticut, USA. BioXcel has more than 60 global clients ranging from pre-IPO biotech's to large bio-pharmaceutical, CROs, diagnostic and medical device companies. Corporate expertise spans the Drug Development Lifecycle: from drug discovery/development to product launch to post-marketing LOE strategy. BioXcel understands the dynamics of this continuum allowing us to customize each engagement to align with your specific business needs.

BioXcel has a unique and cost-effective global hybrid delivery model which capitalizes on an experienced management team of US-based executives, (collectively over 150 years of experience with bio-pharmaceutical companies) and the BioXcel Analytical and Commercial Center (BACC) based in India. The BACC offers a broad range of highly-skilled professionals (PhD, MD, MBA, Patent Agents) with analytics expertise in scientific, clinical/medical, intellectual property and business disciplines.

Business Analytics:

-
-
-
-
-
-
-

Cellworks Research India Pvt. Ltd.

3rd Floor, West Wing, Neil Rao Tower,
118 Road 3, EPIP, Whitefield
Bangalore 560066
India

2006
90
Private

Cellworks has more than 20 active collaborations with academic and commercial partners. Cellworks has prospective validations of in-silico predictions of combination therapies, drug targets and biomarkers in Oncology, RA, Pigmentation and diabetes.

Selected as a partner with AZ on an EU FP07 project on TB

Cellworks technology is being used to study target vulnerability

Won a DBT grant to prototype a new strain of e-coli that create chiral synthons in-situ with very high yields.

Multiyear agreement with a leading Pharma company in California. Cellworks technology will be used to study target validation and patient subgroup classification studies. Tremendous savings in cost and timelines are anticipated.

Collaboration on Oncology Preclinical project with top tier Pharma company. Cellworks to provide the Virtual Biology based assay capabilities which will shorten time for target validation and patient stratification studies. Will be announced in 2010.

Anticipating the closure on a multiyear grant in the area of Drug resistance TB. Cellworks is the principal driver of this grant along with a world class top tier Pharma partner. Results to be announced 4Q10.

Anticipating the announcement to of a Collaboration program in Type II diabetes, with a top tier Pharma major, to be announced before end of 2011.

CWG_Onco1	Preclinical	Lung Cancer	Currently going through Invitro validation
CWG_Onco2	Preclinical	Colo Rectal	Currently going through invitro validation
CWG_inflm1	Preclinical	RA	Invitro

Connexios Life Sciences Pvt. Ltd.




Incorporated:
Employees:
Ownership:


Highlights of the Platform include:

-
-
-

Curevac GmbH



	First in man data for CV9103 from Phase IIa are expected by 4Q10. First in man data for CV9201 from Phase IIa are expected in 2H11.
In May 2010 CureVac received €27.6 million in its third financing round by dievini Hopp BioTech holding GmbH & Co. KG.	



Cydex Pharmaceuticals, Inc.

Theron Odlaug, Chief Executive Officer

10513 West 84th Terrace
 Lenexa, KS 66214
 USA
www.cydexpharma.com

CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its Captisol® technology. Captisol is currently incorporated in five FDA approved medications and marketed by four of the company’s licensees: Pfizer, Bristol-Myers Squibb and Prism Pharmaceuticals. In addition, the company is supporting drug development efforts with more than 40 other companies worldwide. The company maintains patents in the U.S. and worldwide for its Captisol technology and Captisol enabled products. After 17 years of experience, CyDex has also built a comprehensive FDA Manufacturing and Safety Drug Master File. For additional information on business development opportunities, please contact Richard White at rwhite@cydexpharma.com or 913-685-8850. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit www.cydexpharma.com.


The advanced drug formulation technology of CyDex, Captisol®, is based on a modified cyclodextrin molecule that enables creation of new products by significantly improving the solubility, stability, bioavailability, safety and dosing of active pharmaceutical ingredients (APIs).

Captisol® is one of a series of anionically charged sulfobutyl ether β-cyclodextrins (SBE-CDs) that were originally synthesized and patented by scientists from the University of Kansas Higuchi Biosciences Center for Drug Delivery Research.

Two Captisol-enabled® drugs, Vfend I.V. and Zeldox/Geodon for Injection, have been brought to market in the US and EU by Pfizer Inc., a CyDex corporate partner. Pfizer also recently received approval for Vfend I.V. in Japan.

Melphalan CDX-353	Phase II, IIa, IIb	Oncology
Clopidogrel PM-103	Phase II, IIa, IIb	Cardiovascular
Topiramate	Phase II, IIa, IIb	Neurology
Budesonide/ Azelastine CDX-313	Phase II, IIa, IIb	Pulmonary - Allergy
Fosphenytoin	Phase III	Neurology

Dabur Research Foundation



DesignMedix, Inc.

Development Centre For Biotechnology

101, Lane 169, Kangning Street Taipei 221 Taiwan		
1984 450 Other	<p>March, 2010 - DCB gave a presentation at the Biological Manufacturing World Asia 2010 conference. Dr. Wei-Kuang Chi, VP of DCB, was one of the panelists introducing Asia as a new emerging player for contract manufacturing business.</p> <p>October, 2008 - Merck KGaA opens Asian Technology and Training Center in the DCB campus. In April 2008, DCB's modified enterotoxin (LThaK) for nasal spray influenza vaccines received IND approval in Taiwan.</p> <p>May, 2007 - The CGMP Biopharmaceutical Pilot Plant Facility of DCB joined Biopharmaceuticals Production Alliance Network of Boehringer Ingelheim.</p>	<p>Partnership for DCB's LThaK adjuvant during clinical development.</p> <p>Submit IND (FDA) for biologics or small molecule drugs.</p> <p>International collaboration on early stage development of biologics.</p>

DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug (IND) approvals.

DCB is dedicated to realizing the vision of becoming an "Internationally Outstanding Preclinical Research and Service Institute for Biopharmaceutical Development". This goal is to be achieved by building world-caliber infrastructures, establishing key technologies for preclinical development, and fostering the growth of highly-trained technology and business teams. In the long run, these efforts should help bring about success stories of new drug development in Taiwan, and catalyze vigorous growth and prosperity for Taiwan's biotech-pharma industry.

DCB also facilitates technology cooperation and product commercialization processes by employing suitable business models covering: patent licensing, technology transfer, strategic alliance, research collaboration, contract service, and spin-out venture. DCB's objective is to help create win-win opportunities for partnership stakeholders with optimized coordination and integration of resources in Taiwan, and eventually, to facilitate business expansion into the global biotech-pharma market.

Biopharmaceutical; biologics; small molecules; botanicals; preclinical toxicology; cGMP biopharmaceutical/protein clinical production; vaccine adjuvant; drug formulation

In 2007, the CGMP Biopharmaceutical Pilot Plant Facility of DCB signed a priority-cooperation agreement with Boehringer Ingelheim GmbH (Germany) and joined its Production Alliance Network.

DCB formed a technology cooperation with Crucell, N.V. (Holland) in 2007 for technology transfer of monoclonal antibody producing cell lines and further cooperation.

Merck KGaA (Germany) established its first Asian Technology and Training Center (ATTC) on the campus of DCB headquarters in 2008. In addition to providing technical services, application supports and user-training platforms for Merck's customers in the region, the center also serves as a business link for DCB's CGMP Biopharmaceutical Pilot Plant Facility in its international business networks.

DCB-SLE1	Phase II, IIa, IIb	Systemic Lupus Erythematosus	Phase II clinical trials undergoing in Taiwan at TVGH and TSGH
DCB-CA2	Preclinical	Cancer Cachexia	Patch production and efficacy validation completed
INFa-Fc Fusion Protein	Preclinical	Hepatitis C	Received from US-FDA Pre-IND consultation comments for pre-clinical and phase I study designs
Anti-herpes simplex virus (HSV) antibodies	Optimized Lead	Prophylax and treatment of Herpes Simplex Virus (HSV) infection	The preliminary animal studies show that these mAbs have prophylactic and therapeutic effect for HSV infection. Patents have been filed.
Contract Manufacturing Service (CGMP Biopharmaceutical Pilot Plant Facility)	Other	N/A	CGMP certificate for compliance with ICH and WHO guidelines in 2005; A drug master file (DMF type V, No.19164) was registered with the US FDA in 2006.

Contract Research Service (Center of Toxicology and Preclinical Sciences)	Other	N/A	Technical and support procedures are in full compliance with Taiwan DOH, OECD and US FDA GLP guidelines.
FLB5, anti-IL-20 mAb (Humanized)	Preclinical	,Rheumatoid Arthritis, IL-20-induced inflammatory diseases	Preclinical studies will be finished in 2011. Filing of IND will begin in 2012. Several patents have been granted.
LTh(aK) adjuvant	IND Filed	nasal influenza vaccine, bacterial capsular polysaccharide vaccine and allergy vaccine.	The clinical phase I study protocol for this project [the mixture of LTh(aK) adjuvant with seasonal flu antigens (trivalent split flu)] was approved by the IRB of National Taiwan University Hospital in Oct. 2008.
Long-acting Amikacin Inhalation	Research	Nosocomial pneumonia	PLGA loaded with Amikacin are intended to provide prolonged and increased concentration of the drug in the lung to improve delivery of incorporated drug to the lung. Looking for a partner to co-develop this technology.
Ropivacaine In-Situ Gel for Injection	Research	Pain control, Post-surgical pain control	The entrapped Ropivacaine will be continuously releasing from the gelling matrix for up to 72 hours. Looking for a partner to co-develop this technology.

Eli Lilly & Company

Jude E. Onyia
Uma Kuchibhotla
Hardik Valera
Mukta Arora
Rajiv Gulati

Lilly Corporate Center
Indianapolis, IN 46285-0001
USA

1876
40360
Public

LLY

We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people.

Discovering and developing innovative therapies for many of the world's unmet medical needs is at the core of Lilly Research Lab's (LRL) mission.


Approximately 7,000 people work in LRL in the U.S. and other countries around the world. Research and development locations in the United States include several sites in Indiana and California.

The most recent listing of sites has been revised to United States, Canada, China, England, Japan, Singapore, Spain, and a joint venture facility in Australia. In addition, LRL conducts clinical research in more than 50 countries around the world.

At Lilly, we value partnerships. Our history has proven—and our strategy continues to prove—that by working together, we can discover, develop, and deliver the innovative pharmaceutical therapies that will help people live longer, healthier, and more active lives. We seek the best ideas, capabilities, and research available, whatever the source. Having excellent in-house talent and resources is one of the pillars of our R&D success, but at the same time, we're excited about the opportunities that exist to collaborate. Great work is being done in all corners of the world and in multiple settings. Our goal is to find it, advance it, and put it to work for the patients who need it.

Semagacestat	Phase III	Alzheimer's
Solanezumab	Phase III	Alzheimer's
GLP-1 Fc	Phase III	Diabetes
IMC-11F8	Phase III	NSCLC
IMC-1121B	Phase III	Breast Cancer and Gastric Cancer
Tasisulam	Phase III	Melanoma
IL-17 antibody	Phase II, IIa, IIb	Rheumatoid Arthritis
IL-23 antibody	Phase II, IIa, IIb	Psoriasis
iGluR5 antagonist	Phase II, IIa, IIb	Pain
IL-1beta antibody	Phase II, IIa, IIb	Diabetes

www.eraconsulting.com





www.fulcrumpharma.com

G7 Synergon Pvt. Ltd.




www.g7synergon.in
Incorporated:
Employees:
Ownership:

<i>Recent</i>	<i>Upcoming</i>


Biocon India Pvt. Ltd.


BIONEEDS PRECLINICAL SERVICES

-Ocimum



-
-
-
-





Genotypic Technology Pvt. Ltd.

#259, Apurva, 4th Cross, 80 Feet Road,
R.M.V II Stage
Bangalore 560094
India

1998
60
Private

SAP
GAllx
Agri Genomics link

Workshop on NGS sequencing along with illumina.
Workshop on Targeted resequencing along with illumina and AGilKent.
NGS session in SBC.

Biointerpreter: <http://genotypic.co.in/biointerpreter.html?mnu=1>

On Market

Microarray Data Analysis

MedRunner- <http://genotypic.co.in/medrunner.html?mnu=1>

On Market

Literature mining

SeqQC- <http://www.genotypic.co.in/SeqQC.html>

On Market

NGS Sequence Data QC tool - free download

Multiplexing in On-Array DNA capture

On Market

Low cost targeted gene sequencing

Deven Shah

709 Swedeland Road
King of Prussia, PA 19406
USA


1875
100,000
Public


GSK


GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit www.gsk.com.

Seretide/Advair	On Market	Respiratory
Avodart	On Market	Urogenital
Tyverb/Tykerb	On Market	Oncology
Coreg	On Market	Cardiovascular
Pediarix	On Market	Pediatric Vaccine

Grunenthal GmbH









Helsinn Healthcare SA





Incozen Therapeutics Pvt. Ltd.




Intas Biopharmaceuticals Limited

--

-
-
-
-
-
-
-
-
-
-


Intrexon Corporation



Inviragen, Inc.



-
-
-
-




Jubilant Biosys Pvt. Ltd.






www.kemwellpharma.com



Livwel Therapeutics, Inc.



www.livweltherapeutics.com



Lupin Ltd. (Biotech Div.)

Gat 1156, Village Ghotawade, Mulshi Taluka Pune 411042 India	
1968 10,000 Public	
LUP	


2011), Lupin reported strong performance with topline growth of 21% and 40% in profitability!

Lupin has over eight manufacturing sites in India and is amongst the world's leaders in anti-TB drug manufacturing. The scale of our fermentation facilities exceeds 100,000 L and our Pharmaceutical sites have the WHO Geneva, US FDA, EMEA, UK MHRA and TGA certifications.



Lupin has now ventured into the Biologics space and currently has both Microbial and Mammalian manufacturing capabilities. A dedicated team of scientists specializing in Biotech research have been working constantly to develop a basket of proteins. Lupin is also exploring collaborative arrangements to expedite its business in this segment. The company is targeting both at Biosimilar and New Biological Entities (NBEs), in order to develop new cost effective products, free from side effects, and in compliance with the existing regulatory guidelines. Biotech research will be the new engine of differentiation for the company.

As a stepping stone to its Biotech venture, Lupin's team of dedicated scientists has successfully developed certain Proprietary Vectors in conventional host systems for producing High Performance Clonal Cell Lines, which aid in enhanced expression of therapeutic proteins. Our expertise lies in the development of hyper expressing clones for "difficult to express" therapeutic proteins in suitable Prokaryotic (E.Coli) and Pichia expression system.

Cloning services for E Coli & Pichia expression systems	Research	For difficult to express proteins, which can be expressed as intracellular soluble proteins
Licensing of the proprietary vector(s) via cloning service	Research	For soluble expression of difficult to express structurally complex proteins which tend to form inclusion bodies within the cell and for rapid in-situ screening of bacterial transformants.



www.makrocare.com



www.medex.com.co

www.medtrack.com

-
-

www.merck.com/licensing/

New York Stock Exchange: MRK

Bombay Stock Exchange: MERCK

Novartis India Limited



Incorporated:
Employees:
Ownership:
Other: NOVN.VX

Sandoz Generics:

Consumer Health:


Our Mission:

Novo Nordisk A/S



www.novonordisk.com

New York Stock Exchange: NVO



Polyclone Bioservices Pvt. Ltd.



www.pyclonebio.com

Quintiles



www.quintiles.com

www.recordati.com

Italian Stock Exchange: REC.MI

-
-
-
-
-
-
-

www.roche.com


Other: RO.S

www.rxmd.com

www.sanofipasteur.com

New York Stock Exchange: SNY

-
-
-
-



Incorporated:
Employees:
Ownership:

<i>Recent</i>	<i>Upcoming</i>

Toll Mfg:

Export Markets:

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>

Incorporated:
Employees:
Ownership:
NASDAQ: SHPGY

www.shb.com

www.sppirx.com

NASDAQ: SPPI

www.invest.vic.gov.au/BiotechnologyLifeSciences

-
-
-

www.strandls.com

www.takeda.com


Tokyo Stock Exchange: 4502:JP

-
-
-
-
-
-
-
-
-
-


www.tristargroup.us

Analysis of target expression including prognosis on >50,000 archived donor samples of prevalent tumor types. Validation of clinical biomarkers in tissues, serum etc. (CNS, GI, CVD & Respiratory)

Unique Biotech Limited




-
-



-
-
-
-
-
-

-
-
-
-
-

Vivo Ventures, LLC



Zydus Cadila Healthcare Ltd.

--

532321

--

--